Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intron-A/Aldara Combination for BCC
NCT00581425Phase 4Completed
- Sponsor
- UTHealth Houston
- Start
- Dec 2007
- Primary completion
- Sep 2011
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon alfa-2b and imiquimod in basal cell carcinoma (BCC), sponsored by UTHealth Houston. Primary endpoint: Resolution of Basal Cell Carcinoma at 2 years. Started Dec 2007; status: completed.
02
Drugs
interferon alfa-2bimiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00581425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581425.